Clinical trial
The Use of Polyclonal Anti-T-Lymphocyte Globulin to Prevent Progression of Autoimmune Beta-Cell Destruction in Recent Type 1 Diabetes
NCT00190502 is registered in ClinicalTrials.gov with Institute for Clinical and Experimental Medicine as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Use of Polyclonal Anti-T-Lymphocyte Globulin to Prevent Progression of Autoimmune Beta-Cell Destruction in Recent Type 1 Diabetes
- Lead sponsor
- Institute for Clinical and Experimental Medicine
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- November 30, 2000
- Completion date
- December 31, 2007
- Enrollment
- 28
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.